You are here

  • Home
  • Archive
  • Volume 20, Issue 4
  • Trimethoprim-sulfamethoxazole monotherapy should not be used for treatment of severe methicillin-resistant Staphylococcus aureus infections

Article Text

Article menu
Download PDFPDF
Therapeutics/Prevention
Randomised controlled trial
Trimethoprim-sulfamethoxazole monotherapy should not be used for treatment of severe methicillin-resistant Staphylococcus aureus infections

https://doi.org/10.1136/ebmed-2015-110241

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Footnotes

    • Competing interests SH has received peer-reviewed research grants funded by Pfizer and B Braun, and is a member of the advisory boards of Destiny Pharma, bioMérieux, Novartis and DaVolterra.

    • Patient consent Obtained.

    • Provenance and peer review Commissioned; internally peer reviewed.